Technology | July 07, 2014

Vital Connect HealthPatch MD Biosensor Receives FDA Clearance


July 7, 2014 — Vital Connect announced its HealthPatch MD biosensor has received U.S. Food and Drug Administration (FDA) clearance. The solution is capable of capturing clinical-grade biometric measurements and is the first FDA-cleared medical device that includes a fall detection feature. Designed to support the treatment of a range of diseases and conditions, the HealthPatch MD is a versatile and comprehensive biosensor solution that may be used by healthcare professionals to provide 24-hour, real-time, unattended monitoring of patients’ physiological data or vital signs.

Combined with Vital Connect’s proprietary algorithms, the sensor’s technologies enable the device to provide clinical-grade measurements of the following core health metrics: single-lead ECG (electrocardiogram), heart rate, heart rate variability, respiratory rate, skin temperature, posture including fall detection and severity, and steps. The HealthPatch MD leverages on-board intelligence to perform sophisticated, proprietary SensorFusion algorithms, which process thousands of data points per minute to produce accurate robust measurements.

“We are very proud and excited that the HealthPatch MD has received FDA clearance and can now be sold in the United States for medical use,” said Vital Connect CEO Nersi Nazari. “Together with our partners, we cannot wait to begin implementing solutions using the HealthPatch MD to optimize the way healthcare is delivered in the U.S.”

Healthcare professionals will be able to use the sensor to collect patient data on demand and may be notified when physiological data falls outside selected parameters. The HealthPatch MD is intended to be less obtrusive than other sensors, can be customized for data reporting, operates on Bluetooth 4.0 and provides HIPPA-compliant cloud-based storage and connectivity.

The HealthPatch MD has received regulatory approval (CE mark) for distribution in the European Union, and is licensed and registered by Health Canada for distribution in Canada.

For more information: www.vitalconnect.com


Related Content

News | ECG

March 4, 2026 — HeartBeam, Inc. has announced a commercial partnership with ClearCardio. In addition to serving as ...

Home March 06, 2026
Home
News | ECG

March 3, 2026 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for treating cardiovascular and ...

Home March 04, 2026
Home
News | ECG

Feb. 10, 2026 – AccurKardia, a provider of ECG-based diagnostics technology, recently announced results from a new study ...

Home February 24, 2026
Home
News | ECG

Feb. 18, 2026 — Researchers at the Mount Sinai Kravis Children’s Heart Center led a multicenter effort to develop and ...

Home February 20, 2026
Home
News | ECG

Dec. 10, 2025 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to HeartBeam, Inc. for its 12 ...

Home February 16, 2026
Home
News | ECG

Jan. 8, 2026 — AccurKardia recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the ...

Home January 15, 2026
Home
News | ECG

Jan. 13, 2026 — AliveCor has received U.S. Food and Drug Administration (FDA) clearance for the next generation of KAI ...

Home January 14, 2026
Home
News | ECG

Oct. 8, 2025 — Viz.ai recently launched Viz ACS, a new solution in the Viz Cardio Suite. Designed to unite the acute ...

Home October 09, 2025
Home
News | ECG

Aug. 14, 2025 — During HeartBeam, Inc.'s second quarter 2025 earnings conference call, the medical technology company ...

Home August 15, 2025
Home
News | ECG

July 24, 2025 — Royal Philips has announced a collaboration with Epic to integrate Philips’ suite of cardiac ambulatory ...

Home July 24, 2025
Home
Subscribe Now